Vela Diagnostics Sequencing System for HIV-1 Genotype Testing

Special NoticeActive

Key Takeaways

  • Full and open competition - all businesses eligible to bid
  • Work to be performed in FORT DETRICK, MD
  • Industry: In-Vitro Diagnostic Substance Manufacturing

Contract Details

Notice ID
HT9426-26-NOI-5892
Opportunity Type
Special Notice
Sub-Agency
DEFENSE HEALTH AGENCY (DHA)
Office
ARMY MED RES ACQ ACTIVITY
Posted Date
Wednesday, August 12, 2026
Response Deadline
Thursday, August 27, 2026
PSC Code
6650
Set-Aside
Full & Open Competition
Place of Performance
FORT DETRICK, MD, 21702
Status
Active

Description

Notice of Intent (NOI) to Sole Source Title: Vela Sentosa SQ Next Generation Sequencing (NGS) for FDA Approved HIV-1 Genotype Sequencing Requiring Activity: Walter Reed Army Institute of Research (WRAIR) , Diagnostics and Countermeasures Branch (DCB) Related Notice: HT9426-26-RFI-5892 Product Service Code (PSC): 6550 - In Vitro Diagnostic Substances, Reagents, Test Kits and Sets North American Industry Classification System (NAICS) Code: 325413 - In-Vitro Diagnostic Substance Manufacturing Small Business Size Standard: 1250 employees The Defense Health Agency Contracting Activity (DHACA) on behalf of the Diagnostics and Countermeasures Branch (DCB) at the Walter Reed Army Institute of Research (WRAIR) intends to award a Firm Fixed Price contract on a sole source basis to Vela Diagnostics,

Why This Opportunity Matters

The Department of DEFENSE is seeking responses for in-vitro diagnostic substance manufacturing in FORT DETRICK, MD.